Intraocular pharmacokinetics of a crystalline lipid prodrug, octadecyloxyethyl-cyclic-cidofovir, for cytomegalovirus retinitis

Journal of Ocular Pharmacology and Therapeutics

Volumn 27, Issue 2, 2011, Pages 157-162

  Cheng, Lingyun ^a   Beadle, James R ^b   Tammewar, Ajay ^a   Hostetler, Karl Y ^b   Hoh, Carl ^c   Freeman, William R ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; OCTADECYLOXYETHYL CYCLIC CIDOFOVIR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; AUTORADIOGRAPHY; CHOROID; CONTROLLED STUDY; CYTOMEGALOVIRUS RETINITIS; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG STRUCTURE; LIQUID SCINTILLATION COUNTING; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MICROCRYSTALLINE SUSPENSION; NONHUMAN; RABBIT; RETINA; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VITREOUS BODY;

ANIMALS; ANTIVIRAL AGENTS; AUTORADIOGRAPHY; CYTOMEGALOVIRUS RETINITIS; CYTOSINE; EYE; INTRAVITREAL INJECTIONS; PHOSPHONIC ACIDS; PRODRUGS; RABBITS;

EID: 79955028243     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2010.0155     Document Type: Article

References (20)

1. Sacu, S., Michels, S., Prager, F., et al. Randomised clinical trial of intravitreal avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results. Eye 23:2223-2227, 2009.
2. Bressler, N.M., Chang, T.S., Fine, J.T., Dolan, C.M., and Ward, J. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Arch. Ophthalmol. 127:13-21, 2009.
3. Brown, D.M., Michels, M., Kaiser, P.K., et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the anchor study. Ophthalmology 116:57-65.e55, 2009.
4. Ramchandran, R.S., Fekrat, S., Stinnett, S.S., and Jaffe, G.J. Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results. Am. J. Ophthalmol. 146:285-291, 2008.
5. Taban, M., Lowder, C.Y., and Kaiser, P.K. Outcome of flu-ocinolone acetonide implant (Retisert trade mark) re-implantation for chronic noninfectious posterior uveitis. Retina 28:1280-1288, 2008.
6. Mohammad, D.A., Sweet, B.V., and Elner, S.G. Retisert: is the new advance in treatment of uveitis a good one? Ann. Pharmacother. 41:449-454, 2007.
7. Morlet, N., Young, S., Naidoo, D., Graham, G., and Coroneo, M.T. High dose intravitreal ganciclovir injection provides a prolonged therapeutic intraocular concentration. Br. J. Oph-thalmol. 80:214-216, 1996. (Pubitemid 26090348)
8. Tammewar, A.M., Cheng, L., Hostetler, KY., et al. In-traocular properties of an alkoxyalkyl derivative of cyclic 9-(s)-(3-hydroxyl-2- phosphonomehoxypropyl) adenine, an intravitreally injectable anti-hcmv drug in rabbit and guinea pig. J. Ocul. Pharmacol. Ther. 23:433-444, 2007. (Pubitemid 350202477)
9. Cheng, L., Hostetler, KY., Lee, J., et al. Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir. Invest. Ophthalmol. Vis. Sci. 45:4138-4144, 2004. (Pubitemid 39411172)
10. Hostetler, KY. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce tox-icity: current state of the art. Antiviral Res. 82:A84-A98, 2009.
11. Cheng, L., Hostetler, KY., Chaidhawangul, S., et al. Treat-ment or prevention of herpes simplex virus retinitis with intravitreally injectable crystalline 1-o-hexadecylpro-panediol-3-phospho-ganciclovir. Invest. Ophthalmol. Vis. Sci. 43:515-521, 2002. (Pubitemid 34113237)
12. Aldern, K.A., Ciesla, S.L., Winegarden, K.L., and Hostetler, KY. Increased antiviral activity of 1-o-hexadecyloxypropyl-[2-(14)c]cidofovir in mrc-5 human lung fibroblasts is ex-plained by unique cellular uptake and metabolism. Mol. Pharmacol. 63:678-681, 2003. (Pubitemid 36297340)
13. Beadle, J.R, Hartline, C., Aldern, K.A., et al. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob. Agents Che-mother. 46:2381-2386, 2002. (Pubitemid 34793439)
14. Cheng, L., Hostetler, KY., Gardner, M.F., et al. Intravitreal pharmacokinetics in rabbits of the foscarnet lipid prodrug: 1-o-octadecyl-sn- glycerol-3-phosphonoformate (odg-pfa). Curr. Eye Res. 18:161-167, 1999. (Pubitemid 29213830)
15. Cundy, K.C., Lynch, G., Shaw, J.P., Hitchcock, M.J., and Lee, W.A. Distribution and metabolism of intravitreal cido-fovir and cyclic hpmpc in rabbits. Curr. Eye Res. 15:569-576, 1996. (Pubitemid 26162460)
16. Wan, W.B., Beadle, J.R, Hartline, C., et al. Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus rep-lication in vitro. Antimicrob. Agents Chemother. 49:656-662, 2005. (Pubitemid 40175677)
17. Driot, JY., Novack, G.D., Rittenhouse, K.D., Milazzo, C., and Pearson, P.A. Ocular pharmacokinetics of fluocinolone acetonide after retisert intravitreal implantation in rabbits over a 1-year period. J. Ocul. Pharmacol. Ther. 20:269-275,2004. (Pubitemid 38849806)
18. Avery, R.L., Pieramici, D.J., Rabena, M.D., et al. Intravitreal bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363-372.e365, 2006.
19. Abraham, P., Yue, H., and Wilson, L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovas-cular age-related macular degeneration: Pier study year 2. Am. J. Ophthalmol. 150:315-324.e311, 2010.
20. Jaffe, G.J., Martin, D., Callanan, D., et al. Fluocinolone acetonide implant (retisert) for noninfectious posterior uve-itis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 113:1020-1027, 2006. (Pubitemid 43795240)